Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 87,939 |
|
|||||
| News | - | ||||||
| Day High | 8.4094 | Low High |
|||||
| Day Low | 7.98 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| ALX Oncology Holdings Inc | ALXO | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.175 | -2.11% | 8.125 | 12:05:54 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 8.11 | 7.98 | 8.4094 | 8.30 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,262 | 87,939 | US$ 8.22 | US$ 722,423 | - | 3.9357 - 12.33 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 12:06:19 | 3 | US$ 8.12 | USD |
ALX Oncology Holdings Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 405.03M | 49.82M | - | 0 | -123.48M | -2.48 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ALX Oncology News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/13/2023 | 15:05 | GlobeNewswire Inc. | ALX Oncology Reports Third Quarter 2023 Financial Results.. |
| 11/13/2023 | 15:03 | Edgar (US Regulatory) | Form 8-K - Current report |
| 11/01/2023 | 15:05 | GlobeNewswire Inc. | ALX Oncology Announces November Investor Conference.. |
| 10/10/2023 | 15:05 | GlobeNewswire Inc. | ALX Oncology Announces Closing of Public Offering, Including.. |
| 10/06/2023 | 05:06 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/06/2023 | 05:05 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 10/05/2023 | 07:00 | GlobeNewswire Inc. | ALX Oncology Announces Pricing of Public Offering |
| 10/04/2023 | 16:21 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/04/2023 | 16:21 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 10/04/2023 | 15:10 | GlobeNewswire Inc. | ALX Oncology Announces Proposed Public Offering |
| 10/04/2023 | 07:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 10/03/2023 | 09:03 | IH Market News | Keep An Eye Out: Pre-Market Movers And Recommendations |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALXO Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 8.83 | 9.30 | 7.35 | 8.21 | 401,242 | -0.705 | -7.98% |
| 1 Month | 9.11 | 10.49 | 7.35 | 8.70 | 371,770 | -0.985 | -10.81% |
| 3 Months | 4.89 | 10.49 | 4.64 | 7.70 | 1,363,686 | 3.24 | 66.16% |
| 6 Months | 8.25 | 10.49 | 3.9357 | 7.53 | 736,694 | -0.125 | -1.52% |
| 1 Year | 11.33 | 12.33 | 3.9357 | 7.39 | 491,853 | -3.21 | -28.29% |
| 3 Years | 72.36 | 117.45 | 3.9357 | 22.98 | 375,035 | -64.24 | -88.77% |
| 5 Years | 30.44 | 117.45 | 3.9357 | 23.99 | 348,558 | -22.32 | -73.31% |
ALX Oncology Description
| ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. |
